Semaglutide is the active molecule. Ozempic is one brand name for a drug that contains it. Every dose of Ozempic is semaglutide, but not all semaglutide is Ozempic. The distinction matters for what it's approved for, what it costs, and what quality controls it was manufactured under.
The confusion is understandable. When Ozempic became the shorthand for GLP-1 weight loss drugs across mainstream media, the brand name became the category, the same way people say "Kleenex" for tissues or "Google" for searching. Doctors and patients started using "Ozempic" and "semaglutide" interchangeably. They're related, but not identical, and the differences matter depending on what you're trying to achieve and how you're accessing the drug.
The molecule and the brands, what's actually in the pen
Semaglutide is a GLP-1 receptor agonist, a peptide molecule that mimics the naturally occurring GLP-1 hormone your body produces after eating. It was developed by Novo Nordisk and has been approved by the FDA under three different brand names for three different purposes.
| Brand name | Active ingredient | FDA-approved use | Dose range | Form |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes, blood sugar control, cardiovascular risk reduction | 0.25–2mg weekly | Injectable pen |
| Wegovy | Semaglutide | Chronic weight management in adults and adolescents with obesity | 0.25–2.4mg weekly (up to 7.2mg HD) | Injectable pen |
| Rybelsus | Semaglutide | Type 2 diabetes | 3–14mg daily | Oral tablet |
The active molecule is identical across all three. What differs is the approved indication, the dose, and the delivery mechanism. Ozempic is not approved for weight loss, Wegovy is. Prescribing Ozempic for weight loss is off-label use, which is legal but not what the FDA reviewed the drug for at those doses.
Why Ozempic became the word for everything
Ozempic launched first and became the cultural reference point. When celebrities and social media documented dramatic weight loss, they said "Ozempic", not "semaglutide" and certainly not "Wegovy." The brand name stuck to the entire category in the public imagination even as Wegovy (the weight-loss-approved version) became the more appropriate reference for that use case.
Clinicians contributed to the confusion by sometimes using the generic name "semaglutide" when discussing the treatment category across all three brands. Patients hearing "semaglutide" assumed it meant Ozempic. It might mean Wegovy. It might mean compounded semaglutide. Context matters.
Compounded semaglutide, the third category
Beyond the branded products, a significant and legally distinct category emerged during the drug shortage period of 2023–2025: compounded semaglutide prepared by licensed 503A compounding pharmacies. This is where the distinction becomes most important.
Active ingredient: Identical, semaglutide is semaglutide at the molecular level.
Manufacturing oversight: Ozempic undergoes FDA premarket review with strict quality, potency, and sterility standards. Compounded versions are prepared by state-licensed pharmacies under USP 797 standards, more rigorous than over-the-counter supplements, less than FDA-approved manufacturing.
FDA approval status: Ozempic, FDA approved. Compounded semaglutide, not FDA approved. The FDA does not review compounded drugs for safety and efficacy before dispensing.
Cost: Ozempic/Wegovy: $900–1,500/month list price. Compounded semaglutide: $149–299/month through many providers.
Legal status 2026: Compounded semaglutide availability tightened significantly after the FDA resolved the shortage in early 2025. 503A pharmacies are now limited to four or fewer prescriptions per month for compounded semaglutide, physician oversight and clinical justification are required.
Some compounded products also contain semaglutide in salt form (sodium or acetate) rather than the base form used in FDA-approved products. The FDA has stated there is no evidence that salt forms are equally safe or effective. This is worth confirming with any compounding pharmacy.
What "Ozempic face" actually means, and why it applies to all forms
One of the most searched GLP-1 side effect terms is "Ozempic face", the facial volume loss and sagging that can occur with rapid weight loss. It is not an Ozempic-specific phenomenon. It occurs with any significant weight loss, including Wegovy, compounded semaglutide, tirzepatide, and non-pharmacological methods. The brand name stuck to the effect the way it stuck to the drug class, but the mechanism is simply rapid fat loss from facial tissue, present regardless of how the weight loss was achieved.
Wegovy HD, the 2026 development worth knowing
In March 2026, the FDA approved Wegovy HD, a high-dose formulation of semaglutide at 7.2mg weekly, nearly triple the previous maximum dose of 2.4mg. The clinical rationale is that a subset of patients at the 2.4mg maintenance dose continue to respond and could benefit from further dose escalation. This puts semaglutide back in direct competition with tirzepatide, which produces approximately 20% weight loss versus semaglutide's 15% at standard doses in head-to-head trials.
Which version is right for you
If you have type 2 diabetes and cardiovascular disease: Ozempic or Wegovy under physician prescription, the SELECT cardiovascular outcomes trial gives semaglutide a mature evidence base for this indication.
If weight management is the primary goal: Wegovy (or tirzepatide/Zepbound, which outperforms semaglutide in head-to-head trials). The Novo Nordisk subscription programme introduced in March 2026 brings Wegovy to approximately $249–329/month for self-pay patients, significantly more accessible than before.
If cost is the primary barrier: Compounded semaglutide remains available with appropriate physician oversight. Verify that your pharmacy uses base-form semaglutide (not a salt form), operates under USP 797 standards, and provides batch-specific COA documentation.
Compounded semaglutide is not a generic version of Ozempic. A generic requires FDA approval confirming bioequivalence. No FDA-approved generic semaglutide exists as of June 2026, patent exclusivity for Novo Nordisk's formulations remains active. Compounded versions are legally prepared alternatives, not generics.